vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-1159Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSОПЫТ ПРИМЕНЕНИЯ ЦИКЛОСПОРИНА В СОЧЕТАНИИ С РАЗНЫМИ РЕЖИМАМИ ВВЕДЕНИЯ МЕТОТРЕКСАТА У БОЛЬНОЙ ТЯЖЕЛЫМ СИСТЕМНЫМ ВАРИАНТОМ ЮВЕНИЛЬНОГО РЕВМАТОИДНОГО АРТРИТАEXPERIENCE OF SEVERE SYSTEM TYPE OF JUVENILE RHEUMATOID ARTHRITIS TREATMENT WITH CYCLOSPORINE IN COMBINATION WITH DIFFERENT METHOTREXATE REGIMENБзароваТ.М.BzarovaT.M.АлексееваЕ.И.AlexeevaE.I.ВалиеваС.И.ValievaS.I.ЛисицинА.О.LisitsinA.O.Научный центр здоровья детей РАМН, МоскваРоссияScientific Center of Children’s Health, Russian Academy of Medical Sciences, MoscowRussian Federation20092309201584Вопросы современной педиатрии142150Copyright © Бзарова Т., Алексеева Е., Валиева С., Лисицин А., 20092009Бзарова Т., Алексеева Е., Валиева С., Лисицин А.Bzarova T., Alexeeva E., Valieva S., Lisitsin A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/1159ReferencesSzer I. S., Kimura Y., Malleson P. N. et al. Arthritis in children and Adolescents. Juvenile Idiopathic Arthritis. Oxford: University Press. 2006. 456 p.Szer I. S., Kimura Y., Malleson P. N. et al. Arthritis in children and Adolescents. Juvenile Idiopathic Arthritis. Oxford: University Press. 2006. 456 p.Cassidy J., Petty R. eds. Texbook of paediatric rheumatology, 5th Ed. Elsevier Saunders. 2005.Cassidy J., Petty R. eds. Texbook of paediatric rheumatology, 5th Ed. Elsevier Saunders. 2005.Бзарова Т.М., Алексеева Е. И., Петеркова В. А. Роль факторов болезни и факторов противоревматической терапии в развитии низкорослости у детей, страдающих ювенильным ревматоидным артритом. Вопросы современной педиатрии. 2006; 5 (5): 13–18.Бзарова Т.М., Алексеева Е. И., Петеркова В. А. Роль факторов болезни и факторов противоревматической терапии в развитии низкорослости у детей, страдающих ювенильным ревматоидным артритом. Вопросы современной педиатрии. 2006; 5 (5): 13–18.Алексеева Е. И., Литвицкий П. Ф. Ревматоидный артрит. Этиология, патогенез. Клиника. Алгоритмы диагностики и лечения. М.: Веди. 2007. 359 с.Алексеева Е. И., Литвицкий П. Ф. Ревматоидный артрит. Этиология, патогенез. Клиника. Алгоритмы диагностики и лечения. М.: Веди. 2007. 359 с.Алексеева Е. И., Шахбазян И. Е. Принципы патогенетической терапии тяжелых системных вариантов ювенильного ревматоидного артрита. Серия «Аутоиммунные болезни». № 5. М. 2002. 127 с.Алексеева Е. И., Шахбазян И. Е. Принципы патогенетической терапии тяжелых системных вариантов ювенильного ревматоидного артрита. Серия «Аутоиммунные болезни». № 5. М. 2002. 127 с.Reiff A., Shaham B., Wood B. P. et al. High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin. Exp. Rheumatol. 1995; 13 (1): 113–118.Reiff A., Shaham B., Wood B. P. et al. High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin. Exp. Rheumatol. 1995; 13 (1): 113–118.Hashkes P. J., Laxer R. M. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005; 294 (13): 1671–1684.Hashkes P. J., Laxer R. M. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005; 294 (13): 1671–1684.Tambic-Bukovac L., Malcic I., Prohic A. Personal experience with methotrexate in the treatment of idiopathic juvenile arthritis. Rheumatism. 2002; 49 (1): 20–24.Tambic-Bukovac L., Malcic I., Prohic A. Personal experience with methotrexate in the treatment of idiopathic juvenile arthritis. Rheumatism. 2002; 49 (1): 20–24.Ravelli A., Viola S., Migliavacca D. et al. The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. J. Pediatr. 1999; 135 (3): 316–320.Ravelli A., Viola S., Migliavacca D. et al. The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. J. Pediatr. 1999; 135 (3): 316–320.Woo P., Southwood T. R., Prieur A. M. et al. Randomized, placebocontrolled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthr. Rheum. 2000; 43 (8): 1849–1857.Woo P., Southwood T. R., Prieur A. M. et al. Randomized, placebocontrolled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthr. Rheum. 2000; 43 (8): 1849–1857.Chikanza I. C. Juvenile rheumatoid arthritis: therapeutic perspectives. Paediatr. Drugs. 2002; 4 (5): 335–348.Chikanza I. C. Juvenile rheumatoid arthritis: therapeutic perspectives. Paediatr. Drugs. 2002; 4 (5): 335–348.Ferraccioli G. F., Gremese E., Tomietto P. et al. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatol. 2002; 41: 892–898.Ferraccioli G. F., Gremese E., Tomietto P. et al. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatol. 2002; 41: 892–898.Tugwell P., Pincus T., Yocum D. et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N. Eng. J. Rheumatol. 1995; 333 (3): 137–142.Tugwell P., Pincus T., Yocum D. et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N. Eng. J. Rheumatol. 1995; 333 (3): 137–142.Garrood T., Scott D. L. Combination therapy with disease modifying anti–rheumatic drugs in rheumatoid arthritis. Bio. Drugs. 2001; 15 (8): 543–561.Garrood T., Scott D. L. Combination therapy with disease modifying anti–rheumatic drugs in rheumatoid arthritis. Bio. Drugs. 2001; 15 (8): 543–561.Алексеева Е. И., Алексеева А.М., Валиева С. И. Влияние инфликсимаба на клинические и лабораторные показатели активности при различных вариантах юношеского артрита. Вопросы современной педиатрии. 2008; 7 (2): 42–54.Алексеева Е. И., Алексеева А.М., Валиева С. И. Влияние инфликсимаба на клинические и лабораторные показатели активности при различных вариантах юношеского артрита. Вопросы современной педиатрии. 2008; 7 (2): 42–54.Guthrie B., Rouster–Stevens K. A., Reynolds S. L. Review of medications used in juvenile rheumatoid arthritis. Pediatr. Emerg. Care. 2007; 23 (1): 38–46.Guthrie B., Rouster–Stevens K. A., Reynolds S. L. Review of medications used in juvenile rheumatoid arthritis. Pediatr. Emerg. Care. 2007; 23 (1): 38–46.Wallace C. A. Current management of juvenile idiopathic arthritis. Best Pract. Res. Clin. Rheumatol. 2006; 20 (2): 279–300.Wallace C. A. Current management of juvenile idiopathic arthritis. Best Pract. Res. Clin. Rheumatol. 2006; 20 (2): 279–300.Papadopoulos N. G., Alamanos Y., Papadopoulos I. A. et al. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study. J. Rheumatol. 2002; 29 (2): 261–266.Papadopoulos N. G., Alamanos Y., Papadopoulos I. A. et al. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study. J. Rheumatol. 2002; 29 (2): 261–266.Aletaha D., Smolen J.S. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford). 2002; 41 (12): 1367–1374.Aletaha D., Smolen J.S. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford). 2002; 41 (12): 1367–1374.Алексеева Е.И., Шахбазян И.Е. Сандиммун–Неорал — новое качество жизни для больных с тяжелым системным ювенильным ревматоидным артритом. Терапевтический архив. 1999; 71 (5): 26–29.Алексеева Е.И., Шахбазян И.Е. Сандиммун–Неорал — новое качество жизни для больных с тяжелым системным ювенильным ревматоидным артритом. Терапевтический архив. 1999; 71 (5): 26–29.Gerloni V., Cimaz R., Gattinara M. et al. Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10 year prospective study. Rheumatol. (Oxford). 2001; 40 (8): 907–913.Gerloni V., Cimaz R., Gattinara M. et al. Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10 year prospective study. Rheumatol. (Oxford). 2001; 40 (8): 907–913.Drosos A. A., Voulgari P. V., Katsaraki A. et al. Influence of cyclosporin A on radiological progression in early rheumatoid arthritis patients: a 42 month prospective study. Rheumatol. Int. 2000; 19 (3): 113–118.Drosos A. A., Voulgari P. V., Katsaraki A. et al. Influence of cyclosporin A on radiological progression in early rheumatoid arthritis patients: a 42 month prospective study. Rheumatol. Int. 2000; 19 (3): 113–118.Sarzi–Puttini P., D'Ingianna E., Fumagalli M. et al. An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis. Rheumatol. Int. 2005; 25 (1): 15–22.Sarzi–Puttini P., D'Ingianna E., Fumagalli M. et al. An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis. Rheumatol. Int. 2005; 25 (1): 15–22.Darmawan J., Rasker J. J., Nuralim H. Ten year radiographic outcome in patients with rheumatoid factor positive rheumatoid arthritis treated with aggressive immunosuppressive combination therapy. J. Rheumatol. Suppl. 2004; 69: 66–69.Darmawan J., Rasker J. J., Nuralim H. Ten year radiographic outcome in patients with rheumatoid factor positive rheumatoid arthritis treated with aggressive immunosuppressive combination therapy. J. Rheumatol. Suppl. 2004; 69: 66–69.Marchesoni A., Battafarano N., Arreghini M. et al. Radiographic progression in early rheumatoid arthritis: a 12 month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatol (Oxford). 2003; 42 (12): 1545–1549.Marchesoni A., Battafarano N., Arreghini M. et al. Radiographic progression in early rheumatoid arthritis: a 12 month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatol (Oxford). 2003; 42 (12): 1545–1549.Gerards A.H., Landewe R.B.M., Prins A.P.A. et al. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann. Rheum. Dis. 2003; 62: 291–296.Gerards A.H., Landewe R.B.M., Prins A.P.A. et al. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann. Rheum. Dis. 2003; 62: 291–296.Fox R.I., Morgan S.L., Smith H.T. et al. Combined oral cyclosporine and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7–hydroxymetho trexate levels when compared with methotrexate alone. Rheumatol. 2003; 42: 989–994.Fox R.I., Morgan S.L., Smith H.T. et al. Combined oral cyclosporine and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7–hydroxymetho trexate levels when compared with methotrexate alone. Rheumatol. 2003; 42: 989–994.Giacomelli R., Cipriani P., Matucci Cerinic M. et al. Combination therapy with cyclosporine and methotrexate in patients with early rheumatoid arthritis soon inhibits TNF–alpha production without decreasing TNF–alpha mRNA levels. An in vivo and in vitro study. Clin. Exp. Rheumatol. 2002; 20 (3): 365–372.Giacomelli R., Cipriani P., Matucci Cerinic M. et al. Combination therapy with cyclosporine and methotrexate in patients with early rheumatoid arthritis soon inhibits TNF–alpha production without decreasing TNF–alpha mRNA levels. An in vivo and in vitro study. Clin. Exp. Rheumatol. 2002; 20 (3): 365–372.Giacomelli R., Cipriani P., Matucci Cerinic M. et al. Combination therapy with cyclosporine and methotrexate in patients with early rheumatoid arthritis soon inhibits TNF–alpha production without decreasing TNF alpha mRNA levels. An in vivo and in vitro study. Clin. Exp. Rheumatol. 2002; 20 (3): 365–372.Giacomelli R., Cipriani P., Matucci Cerinic M. et al. Combination therapy with cyclosporine and methotrexate in patients with early rheumatoid arthritis soon inhibits TNF–alpha production without decreasing TNF alpha mRNA levels. An in vivo and in vitro study. Clin. Exp. Rheumatol. 2002; 20 (3): 365–372.Алексеева Е. И., Шахбазян И. Е., Валиева С. И. Опыт пятнадцатилетнего применения циклоспорина в детской ревматологии. Вопросы современной педиатрии. 2008; 7 (6): 104–117.Алексеева Е. И., Шахбазян И. Е., Валиева С. И. Опыт пятнадцатилетнего применения циклоспорина в детской ревматологии. Вопросы современной педиатрии. 2008; 7 (6): 104–117.
The authors declare that there are no conflicts of interest present.